RE:ANDA - 505(b)(2) Solid1 wrote: The most important point for me was that Jazz/GW Pharma's exclusive rights to New Chemical Entities (NCEs) expired in September 2023, just as Labs' pharma partner was filing its ANDA.
Eye on the ball people. Epidiolex isn't going anywhere as long at the patent litigation is ongoing. Guessing about what this or that may or may not mean is not meaningful. Yes Strachan stated something about ramping up to support this, but they have also stated and confirmed that this is a non-starter as long as the courts are involved.